"Factor Xa Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous factors and drugs that inhibit or block the activity of FACTOR XA.
| Descriptor ID |
D065427
|
| MeSH Number(s) |
D27.505.519.389.745.800.449.500 D27.505.954.502.119.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Factor Xa Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Factor Xa Inhibitors".
This graph shows the total number of publications written about "Factor Xa Inhibitors" by people in this website by year, and whether "Factor Xa Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2014 | 2 | 1 | 3 |
| 2015 | 2 | 0 | 2 |
| 2016 | 4 | 2 | 6 |
| 2017 | 33 | 21 | 54 |
| 2018 | 47 | 19 | 66 |
| 2019 | 23 | 11 | 34 |
| 2020 | 5 | 5 | 10 |
| 2021 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Factor Xa Inhibitors" by people in Profiles.
-
Utilization of anti-factor Xa levels to guide reversal of oral factor Xa inhibitors in the emergency department. Am J Health Syst Pharm. 2022 Jan 01; 79(1):e20-e26.
-
Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial. Am Heart J. 2021 12; 242:115-122.
-
Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients. Expert Rev Clin Pharmacol. 2021 Oct; 14(10):1289-1294.
-
Severe Inflammation, Acute Kidney Injury, and Drug-Drug Interaction: Triple Penalty for Prolonged Elimination of Apixaban in Patients With Coronavirus Disease 2019: A Grand Round. Ther Drug Monit. 2021 08 01; 43(4):455-458.
-
Effect of dexamethasone on direct Xa-inhibitor oral anticoagulant plasma levels in patients with COVID-19. Thromb Res. 2021 09; 205:106-109.
-
Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes. Thromb Res. 2021 09; 205:1-7.
-
Early use of fondaparinux at therapeutic dosage in COVID-19 infection. Minerva Anestesiol. 2021 08; 87(8):958-960.
-
COVID-19-Associated Ischemic Stroke in a Patient on Therapeutic Anticoagulation. Neurologist. 2021 May 05; 26(3):108-111.
-
Diagnosis, management, and outcomes of venous thromboembolism in COVID-19 positive patients: a role for direct anticoagulants? J Thromb Thrombolysis. 2021 May; 51(4):947-952.
-
Personalized prophylactic anticoagulation in hospitalized patients with Covid-19 - The role of anti-Xa monitoring. Clin Microbiol Infect. 2021 08; 27(8):1188-1189.